



AUG 22 2019

Milon Roy  
Director, Regulatory Affairs  
Unichem Pharmaceuticals (USA), Inc.  
777 Terrace Ave., Ste. 102  
Hasbrouck Heights, NJ 07604

Re: Docket No. FDA-2019-P-0076

Dear Ms. Roy:

This letter responds to your citizen petition received on December 28, 2018, requesting that the Food and Drug Administration (FDA) determine whether Zonegran (zonisamide) capsules, 50 milligrams (mg), approved under new drug application 020789, held by Sunovion Pharmaceuticals Inc., has been discontinued for safety or effectiveness reasons.

FDA has reviewed its records and determined that Zonegran (zonisamide) capsules, 50 mg, was not withdrawn from sale for reasons of safety or effectiveness. Thus, FDA will maintain Zonegran (zonisamide) capsules, 50 mg, in the "Discontinued Drug Product List" section of *Approved Drug Products With Therapeutic Equivalence Evaluations* (the Orange Book).

Enclosed is a copy of the *Federal Register* notice that announces the FDA determination. If you require any further information, please feel free to call me at (301) 796-6650.

Sincerely,

Daniel Gottlieb  
Office of Regulatory Policy  
Center for Drug Evaluation and Research

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-P-0076]

Determination That ZONEGRAN (Zonisamide) Capsules, 50 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) has determined that ZONEGRAN (zonisamide) capsules, 50 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

FOR FURTHER INFORMATION CONTACT: Daniel Gottlieb, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6210, Silver Spring, MD 20993-0002, 301-796-6650, [Daniel.Gottlieb@fda.hhs.gov](mailto:Daniel.Gottlieb@fda.hhs.gov).

SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products under an ANDA procedure.

ANDA applicants must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the “listed drug,” which is a version of the drug that was previously approved. ANDA applicants do not

have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).

The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is known generally as the “Orange Book.” Under FDA regulations, drugs are removed from the list if the Agency withdraws or suspends approval of the drug’s NDA or ANDA for reasons of safety or effectiveness or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).

A person may petition the Agency to determine, or the Agency may determine on its own initiative, whether a listed drug was withdrawn from sale for reasons of safety or effectiveness. This determination may be made at any time after the drug has been withdrawn from sale, but must be made prior to approving an ANDA that refers to the listed drug (§ 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that does not refer to a listed drug.

ZONEGRAN (zonisamide) capsules, 50 mg, is the subject of NDA 020789, held by Sunovion Pharmaceuticals Inc., and initially approved on August 22, 2003. ZONEGRAN (zonisamide) is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. ZONEGRAN (zonisamide) capsules, 50 mg, is currently listed in the “Discontinued Drug Product List” section of the Orange Book.

Unichem Pharmaceuticals (USA), Inc., submitted a citizen petition dated December 28, 2018 (Docket No. FDA-2019-P-0076), under 21 CFR 10.30, requesting that the Agency determine whether ZONEGRAN (zonisamide) capsules, 50 mg, was withdrawn from sale for reasons of safety or effectiveness.



After considering the citizen petition and reviewing Agency records and based on the information we have at this time, FDA has determined under § 314.161 that ZONEGRAN (zonisamide) capsules, 50 mg, was not withdrawn for reasons of safety or effectiveness. The petitioner has identified no data or other information suggesting that this drug product was withdrawn for reasons of safety or effectiveness. We have carefully reviewed our files for records concerning the withdrawal of ZONEGRAN (zonisamide) capsules, 50 mg, from sale. We have also independently evaluated relevant literature and data for possible postmarketing adverse events. We have found no information that would indicate that this drug product was withdrawn from sale for reasons of safety or effectiveness.

Accordingly, the Agency will continue to list ZONEGRAN (zonisamide) capsules, 50 mg, in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” delineates, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. FDA will not begin procedures to withdraw approval of approved ANDAs that refer to this drug product. Additional ANDAs for this drug product may also be approved by the Agency as long as they meet all other legal and regulatory requirements for the approval of ANDAs. If FDA determines that labeling for this drug product should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.

Dated: August 16, 2019.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.